Bayesian Clinical Trials. Berry, D. A. *Nat Rev*, 5:27-36, 2006. Editorial, p. 3bibtex @article{ber06bay,
title = {Bayesian Clinical Trials},
volume = {5},
journal = {Nat Rev},
author = {Berry, Donald A.},
year = {2006},
keywords = {teaching-mds,rct,bayesian-methods,review},
pages = {27-36},
citeulike-article-id = {13265478},
posted-at = {2014-07-14 14:09:57},
priority = {0},
note = {Editorial, p. 3},
annote = {excellent review of Bayesian approaches in clinical trials; "The greatest virtue of the traditional approach may be its extreme rigour and narrowness of focus to the experiment at hand, but a side effect of this virtue is inflexibility, which in turn limits innovation in the design and analysis of clinical trials. ... The set of `other possible results' depends on the experimental design. ... Everything that is known is taken as given and all probabilities are calculated conditionally on known values. ... in contrast to the frequentist approach, only the probabilities of the observed results matter. ... The continuous learning that is possible in the Bayesian approach enables investigators to modify trials in midcourse. ... it is possible to learn from small samples, depending on the results, ... it is possible to adapt to what is learned to enable better treatment of patients. ... subjectivity in prior distributions is explicit and open to examination (and critique) by all. ... The Bayesian approach has several advantages in drug development. One is the process of updating knowledge gradually rather than restricting revisions in study design to large, discrete steps measured in trials or phases."}
}

Downloads: 0

{"_id":"exGaHeyQh6aJYK9C9","bibbaseid":"berry-bayesianclinicaltrials-2006","downloads":0,"creationDate":"2018-06-23T20:06:35.125Z","title":"Bayesian Clinical Trials","author_short":["Berry, D. A."],"year":2006,"bibtype":"article","biburl":"http://hbiostat.org/bib/harrelfe.bib","bibdata":{"bibtype":"article","type":"article","title":"Bayesian Clinical Trials","volume":"5","journal":"Nat Rev","author":[{"propositions":[],"lastnames":["Berry"],"firstnames":["Donald","A."],"suffixes":[]}],"year":"2006","keywords":"teaching-mds,rct,bayesian-methods,review","pages":"27-36","citeulike-article-id":"13265478","posted-at":"2014-07-14 14:09:57","priority":"0","note":"Editorial, p. 3","annote":"excellent review of Bayesian approaches in clinical trials; \"The greatest virtue of the traditional approach may be its extreme rigour and narrowness of focus to the experiment at hand, but a side effect of this virtue is inflexibility, which in turn limits innovation in the design and analysis of clinical trials. ... The set of `other possible results' depends on the experimental design. ... Everything that is known is taken as given and all probabilities are calculated conditionally on known values. ... in contrast to the frequentist approach, only the probabilities of the observed results matter. ... The continuous learning that is possible in the Bayesian approach enables investigators to modify trials in midcourse. ... it is possible to learn from small samples, depending on the results, ... it is possible to adapt to what is learned to enable better treatment of patients. ... subjectivity in prior distributions is explicit and open to examination (and critique) by all. ... The Bayesian approach has several advantages in drug development. One is the process of updating knowledge gradually rather than restricting revisions in study design to large, discrete steps measured in trials or phases.\"","bibtex":"@article{ber06bay,\n title = {Bayesian Clinical Trials},\n volume = {5},\n journal = {Nat Rev},\n author = {Berry, Donald A.},\n year = {2006},\n keywords = {teaching-mds,rct,bayesian-methods,review},\n pages = {27-36},\n citeulike-article-id = {13265478},\n posted-at = {2014-07-14 14:09:57},\n priority = {0},\n note = {Editorial, p. 3},\n annote = {excellent review of Bayesian approaches in clinical trials; \"The greatest virtue of the traditional approach may be its extreme rigour and narrowness of focus to the experiment at hand, but a side effect of this virtue is inflexibility, which in turn limits innovation in the design and analysis of clinical trials. ... The set of `other possible results' depends on the experimental design. ... Everything that is known is taken as given and all probabilities are calculated conditionally on known values. ... in contrast to the frequentist approach, only the probabilities of the observed results matter. ... The continuous learning that is possible in the Bayesian approach enables investigators to modify trials in midcourse. ... it is possible to learn from small samples, depending on the results, ... it is possible to adapt to what is learned to enable better treatment of patients. ... subjectivity in prior distributions is explicit and open to examination (and critique) by all. ... The Bayesian approach has several advantages in drug development. One is the process of updating knowledge gradually rather than restricting revisions in study design to large, discrete steps measured in trials or phases.\"}\n}\n\n","author_short":["Berry, D. A."],"key":"ber06bay","id":"ber06bay","bibbaseid":"berry-bayesianclinicaltrials-2006","role":"author","urls":{},"keyword":["teaching-mds","rct","bayesian-methods","review"],"downloads":0},"search_terms":["bayesian","clinical","trials","berry"],"keywords":["bayesian-methods","rct","review","teaching-mds","*import"],"authorIDs":[],"dataSources":["mEQakjn8ggpMsnGJi"]}